First-generation TKIs such as imatinib, which inhibit KIT, PDGFR, and BCR-ABL, revolutionized first-line therapy for GIST and chronic myeloid leukemia (CML) [18,19,20]. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.